

# D

\*click [LINK](#) for an explanation of standardised wording to be used by Scottish Boards regarding decisions on medicines since May 2016 [Link to Formulary](#)

Medicine	Indication	NHS Board Decision*	DTC Supplement	Date
Dabigatran etexilate (Pradaxa®) (995/14)	DVT and PE	Non-formulary - absence of clinician demand	<a href="#">142</a>	Oct/Nov 2014
Dabigatran etexilate (Pradaxa®) (672/11)	For the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more of the following risk factors: <ul style="list-style-type: none"> <li>- previous stroke, transient ischaemic attack, or systemic embolism</li> <li>- left ventricular ejection fraction &lt;40%</li> <li>- symptomatic heart failure, ≥ New York Heart Association (NYHA) Class 2</li> <li>- age ≥75 years</li> <li>- age ≥65 years associated with one of the following: diabetes mellitus, coronary artery disease or hypertension</li> </ul>	Non-formulary - alternatives preferred	<a href="#">127</a> (update) <a href="#">125</a> <a href="#">123</a> (update) <a href="#">112</a> <a href="#">110</a> <a href="#">109</a> <a href="#">85</a> <a href="#">80</a>	May 2013 Mar/Apr 2013 Jan 2013 Dec 2011 Oct 2011 Sep 2011 Dec 2008 June 2008
Dabrafenib 50mg and 75mg hard capsules (Tafinlar®) SMC2131	In combination with trametinib for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.	Available in line with local guidance for prescribing.	<a href="#">174</a>	May 2019
Dabrafenib (Tafinlar®) (1023/15)	Monotherapy treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.  SMC Restriction: for use in patients with unresectable or metastatic BRAFV600 mutation-positive metastatic melanoma who have received no prior therapy.	HOSPITAL ONLY - (Oncology)  Supplied via a Patient Access Scheme	<a href="#">146</a>	Mar 2015

Daclatasvir (Daklinza®) (1002/14)	In combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults. SMC Restriction: use is restricted to patients with significant fibrosis (Metavir scores F3-F4) or compensated cirrhosis.	Formulary  HOSPITAL ONLY - Hepatitis Team	<a href="#">143</a>	Nov/Dec 2014
Daclizumab 150mg/mL solution for injection in prefilled syringe/pen (Zinbryta®) (1216/17)	For use in patients with rapidly evolving severe (RES) relapsing remitting multiple sclerosis (RRMS) or in patients with RRMS with an inadequate response to disease modifying therapy.  SMC Restriction: for use in patients with rapidly evolving severe (RES) relapsing remitting multiple sclerosis (RRMS) or in patients with RRMS with an inadequate response to disease modifying therapy	Discontinued - product license has been withdrawn [April 2018]  <a href="#">MHRA Risk of severe liver injury with daclizumab, July 2017</a>	<a href="#">161</a>	Jun 2017
Dacomitinib 15mg, 30mg and 45mg film-coated tablets (Vizimpro®) SMC2184	As monotherapy, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.	Available in line with local guidance for prescribing	<a href="#">177</a>	Dec 2019
Dalbavancin 500mg powder for concentrate for solution for infusion (Xydalba®) (1105/15)	Treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.  SMC Restriction: for second-line use or when methicillin-resistant Staphylococcus aureus (MRSA) infection is suspected, or on the advice of local microbiologists or specialists in infectious disease, and the patient is initially hospitalised due to ABSSSI, requires intravenous antibiotics, but is eligible for early discharge as soon as their medical condition does not require further inpatient treatment	Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts – decision expected by April 2017	<a href="#">159</a>	Feb 2017
Dalteparin sodium (Fragmin®) (683/11)	VTE	GPs may prescribe under the direction of the Oncology or Haematology Clinic	<a href="#">123</a> (update) <a href="#">104</a>	Jan 2013 Mar 2011

dapagliflozin film-coated tablets (Forxiga®) SMC2577	in adults for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction (LVEF) >40%.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	<a href="#">194</a>	September 2023
Dapagliflozin 10mg film-coated tablets (Forxiga®) SMC2428	in patients with an estimated glomerular filtration rate of $\geq 25$ to $\leq 75$ ml/min/1.73m <sup>2</sup> at treatment initiation, who are receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker (unless these are not tolerated or contraindicated), and have a urine albumin-creatinine ratio of at least 23mg/mmol and/or type 2 diabetes mellitus.	Available in line with national guidance	<a href="#">189</a>	May 2022
Dapagliflozin 10mg film-coated tablets (Forxiga®) SMC2322	Indication under review: in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. In a randomised, double-blind, phase III study, dapagliflozin demonstrated a significant reduction in the composite outcome of hospitalisation for heart failure, urgent heart failure visit and cardiovascular death compared with placebo in patients with heart failure with reduced ejection fraction receiving current standard of care.	available in line with national guidance	<a href="#">184</a>	May 2021
Dapagliflozin plus metformin (Xigduo®) (983/14)	In adults aged 18 years and older with type 2 diabetes mellitus	Formulary	<a href="#">140</a>	Jul/Aug 2014
Dapagliflozin (Forxiga®) (799/12)	To improve glycaemic control in adults aged 18 years and older with type 2 diabetes mellitus	Formulary GP under the direction of Diabetes team  (Formulary - restricted use in	<a href="#">140</a> <a href="#">136</a> <a href="#">124</a>	Jul/Aug 2014 Mar/Apr 2014 Feb 2013

		combination with metformin)		
Dapagliflozin 5mg film coated tablets (Forxiga®) SMC2185	In adults for the treatment of insufficiently controlled type 1 diabetes mellitus as an adjunct to insulin in patients with BMI $\geq 27$ kg/m <sup>2</sup> , when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is local preference for alternative medicines.	<a href="#">177</a>	Dec 2019
Dapoxetine hydrochloride (Priligy®) (987/14)	Premature ejaculation (PE) in adult men aged 18 to 64 years	Not recommended	<a href="#">140</a>	Jul/Aug 2014
Daptomycin (Cubicin®) (449/08)	Complicated skin and soft tissue infections (eSSTIs) in adults	HOSPITAL ONLY	<a href="#">79</a> <a href="#">77</a> <a href="#">65</a> <a href="#">57</a>	May 2008 Mar 2008 Jan 2007 2006
Daptomycin powder for concentrate for solution for injection or infusion (Cubicin®) 1141/16	Treatment of paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections.	Not available as not recommended for use in NHS Scotland	<a href="#">154</a>	May 2016
daratumumab solution for injection and concentrate for solution for infusion (Darzalex®) SMC2536	in combination with lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	<a href="#">195</a>	December 2023
Daratumumab 1,800mg solution for injection (Darzalex®) SMC2447	In combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (AL) amyloidosis. In a phase III study in patients with newly diagnosed AL amyloidosis with at least one affected organ, the addition of	Available in line with national guidance	<a href="#">190</a>	August 2022

	daratumumab to bortezomib, cyclophosphamide and dexamethasone was associated with a significant improvement in complete haematologic response rate.			
Daratumumab 20mg/ml concentrate for solution for infusion and 1,800mg solution for injection (Darzalex®) SMC2416	In combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.  In an open-label, phase III study, the addition of daratumumab to bortezomib, melphalan, and prednisone was associated with a significant improvement in progression-free survival.		<a href="#">189</a>	May 2022
daratumumab 1,800 mg solution for injection (Darzalex®) SMC2469	In combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide-refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy.	Not available as not recommended for use in NHS Scotland	<a href="#">188</a>	April 2022
Daratumumab 1,800mg solution for subcutaneous injection (Darzalex®) SMC2326	Indication under review: in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.  Following a submission under the orphan medicine process, SMC has previously accepted daratumumab concentrate for solution for infusion in combination with bortezomib, thalidomide and dexamethasone is indicated for the treatment	Available in line with local guidance for prescribing	<a href="#">183</a>	March 2021

	of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (SMC2302).			
Daratumumab 20mg/mL concentrate for solution for infusion (Darzalex®) SMC2302	<p>Indication under review: in combination with bortezomib, thalidomide and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.</p> <p>The addition of daratumumab to bortezomib, thalidomide and dexamethasone was associated with a significant improvement in stringent complete response rates in patients with newly diagnosed multiple myeloma who were eligible for autologous stem cell transplant. This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.</p>	Available in line with local guidance for prescribing	<a href="#">183</a>	March 2021
Daratumumab 1,800mg solution for subcutaneous injection (Darzalex®) SMC2304	<p>As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.</p> <p>SMC restriction: for use as a fourth-line treatment option</p>	Available in line with national guidance	<a href="#">181</a>	November 2020
Daratumumab 1,800mg solution for subcutaneous injection (Darzalex®) SMC2301	<p>In combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.</p> <p>SMC restriction: in combination with bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received one prior therapy only.</p>	Available in line with national guidance	<a href="#">181</a>	November 2020

Daratumumab 20mg/mL concentrate for solution for infusion (Darzalex®) SMC2180	In combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. SMC restriction: in combination with bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received one prior therapy only.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	<a href="#">176</a>	Oct 2019
Daratumumab 20 mg/mL concentrate for solution for infusion (Darzalex®) SMC2191	In combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.	Not available as not recommended for use in NHS Scotland	<a href="#">175</a>	Aug 2019
Daratumumab 20mg/mL concentrate for solution for infusion (Darzalex®) SMC No (1205/17)	As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy. SMC restriction: for use as a fourth line treatment option	Available in line with national guidance	<a href="#">159</a> <a href="#">164</a>	Feb 2017 Nov 2017
Darbepoetin alfa (Aranesp®)	Cancer treatment induced anaemia	Not recommended	<a href="#">58</a>	2006
Darbepoetin alfa (Aranesp®) SureClick	Cancer treatment induced anaemia	Not recommended	<a href="#">58</a>	2006
Darifenacin	Overactive bladder	Non-formulary	<a href="#">69</a>	June 2007
Darolutamide 300mg film-coated tablets (Nubeqa®) SMC2604	treatment of adults with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel.	Available in line with national guidance	<a href="#">195</a>	December 2023
Darolutamide 300mg film-coated tablets (Nubeqa®) SMC2297	Darolutamide is indicated for the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.	Available in line with national guidance	<a href="#">182</a>	January 2021
Darolutamide 300mg film-	Treatment of adults with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel.	Not recommended		

coated tablets (Nubeqa®) SMC 2544				
Darunavir 800mg, cobicistat 150mg, emtricitabine 200mg, tenofovir alafenamide 10mg film-coated tablet (Symtuza®) SMC No 1290/18	The treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40kg).	Available in line with National Guidance	<a href="#">167</a>	April 2018
Darunavir (Prezista®) (1069/15)	Once daily darunavir co-administered with low dose ritonavir in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in paediatric patients aged 3 to 12 years and ≥15kg who are 1) treatment-naive or 2) treatment-experienced with no darunavir resistance-associated mutations, plasma-HIV-1 RNA <100,000 copies/mL, and CD4+ count >100x10 <sup>6</sup> cells/L.	Formulary  (Paediatric HIV clinic)	<a href="#">150</a>	June 2015
Darunavir (Prezista®) (948/14)	HIV-1 infection in paediatric patients 12 to 17 years of age	HOSPITAL ONLY - (Paediatrics) Under direction of paediatric HIV specialist in Lothian or Glasgow	<a href="#">136</a>	Mar/Apr 2014
Darunavir (Prezista®) (861/13)	HIV-1	HOSPITAL ONLY	<a href="#">127</a>	May 2013
Darunavir (Prezista®) (707/11)	HIV-1	HOSPITAL ONLY (HIV Clinic)	<a href="#">109</a> <a href="#">95</a> <a href="#">92</a> <a href="#">69</a>	Sept 2011 Feb/Mar 2010 Aug/Sept 2009 June 2007
Darunavir/cobicistat (Rezolsta®) (1081/15)	In combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older. Genotypic testing should guide its use.	Formulary  Hospital only (HIV Clinic)	<a href="#">150</a>  <a href="#">151</a>	July 2015  Sep/Oct 2015
Darvadstrocel 30 million	For the treatment of complex perianal fistulas in adult patients	Not available as not	<a href="#">176</a>	Oct 2019



cells/6mL suspension for injection (Alofisel®) SMC2115	with non-active / mildly active luminal Crohn's disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy.	recommended for use in NHS Scotland		
Daridorexant film coated tablets (Quviviq) SMC2611	Treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning		197 – awaiting publication	May 2024
Dasatinib 20mg / 50mg / 80mg / 100mg and 140mg film-coated tablets (Sprycel®) SMC2192	The treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia in combination with chemotherapy.	Not available as not recommended for use in NHS Scotland	<a href="#">175</a>	Aug 2019
Dasatinib 20mg, 50mg, 80mg, 100mg, 140 mg film-coated tablets (Sprycel®) SMC2142	For the treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib	Available from a specialist centre in another NHS Board	<a href="#">174</a>	May 2019
Dasatinib 20mg, 50mg, 80mg, 100mg and 140mg film-coated tablets (Sprycel®) SMC 1170/16	For the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	<a href="#">157</a>	Nov 2016
Dasatinib 20mg, 50mg, 80mg, 100mg and 140mg film-coated tablets (Sprycel®) SMC 371/07	For the treatment of adult patients with chronic, accelerated or blast phase chronic myelogenous leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesilate.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	<a href="#">68</a> <a href="#">157</a>	May 2007 Nov 2016
Dasatinib (Sprycel®) (370/07)	Chronic myeloid leukaemia (CML)	HOSPITAL ONLY	<a href="#">68</a>	May 2007
Decitabine (Dacogen®) (846/12)	AML	Not recommended	<a href="#">124</a>	Feb 2013
Defatted powder of Arachis hypogaea L., semen (peanuts)	Treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. Palforzia® may be continued in	Not available as not recommended for use in NHS	<a href="#">191</a>	Nov 2022

<p>0.5mg, 1mg, 10mg, 20mg, 100mg oral powder in capsules for opening and 300mg oral powder in sachet (Palforzia®) SMC 2487</p>	<p>patients 18 years of age and older. Palforzia® should be used in conjunction with a peanut-avoidant diet. Palforzia®, compared with placebo, increased the proportion of patients aged 4 to 17 years with peanut allergy who could tolerate, with no more than mild symptoms, a single dose of at least 1,000mg peanut protein (2,043mg cumulative).</p>	<p>Scotland</p>		
<p>Deferasirox, 90mg, 180mg and 360mg film-coated tablets (Exjade®) SMC No (1246/17)</p>	<p>Treatment of chronic iron overload due to frequent blood transfusions (<math>\geq 7\text{mL/kg/month}</math> of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older. Treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:</p> <ul style="list-style-type: none"> <li>- in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (<math>\geq 7\text{mL/kg/month}</math> of packed red blood cells) aged 2 to 5 years,</li> <li>- in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (<math>&lt; 7\text{mL/kg/month}</math> of packed red blood cells) aged 2 years and older,</li> <li>- in adult and paediatric patients with other anaemias aged 2 years and older</li> </ul> <p>Restriction: deferasirox film-coated tablets are restricted to use as for the SMC advice issued for deferasirox dispersible tablets (<a href="#">No.347/07 - accepted for restricted use within NHS Scotland for the treatment of chronic iron overload associated with the treatment of rare acquired or inherited anaemias requiring recurrent blood transfusions. It is not recommended for patients with myelodysplastic syndromes</a>).</p>	<p>Available in line with National Guidance</p>	<p><a href="#">162</a></p>	<p>Aug 2017</p>
<p>Deferasirox 125mg, 250mg, 500mg dispersible tablets (Exjade®) SMC No. (347/07)</p>	<p>Treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate, in adult and paediatric patients aged 2 years and older with rare acquired or inherited anaemias. The current advice relates only</p>	<p>Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice</p>	<p><a href="#">159</a></p>	<p>Feb 2017</p>

	to use in the myelodysplastic syndrome (MDS) population. SMC Restriction: use in patients with MDS with an International Prognostic Scoring System (IPSS) score of low or intermediate -1 risk.	from local clinical experts – decision expected by April 2017		
Deferasirox (Exjade®) (866/13)	Chronic iron overload	Not recommended	<a href="#">127</a>	May 2013
Deferasirox (Exjade®)	Chronic iron overload	HOSPITAL ONLY	<a href="#">66</a>	Feb 2007
Defibrotide (Defitello®) (967/14)	Severe hepatic veno-occlusive disease (VOD)	Non-formulary - absence of clinician demand	<a href="#">139</a>	June/July 2014
degarelix injection (Firmagon) SMC2625	<ul style="list-style-type: none"> <li>for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.</li> <li>as neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.</li> </ul>	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	196 – awaiting publication	February 2024
Degarelix (Firmagon®) (560/09)	Advanced hormone-dependent prostate cancer in adult male patients	GPs may prescribe under the direct of the Urology/ Oncology Clinic	<a href="#">108</a> <a href="#">103</a> <a href="#">102</a> <a href="#">92</a>	Aug 2011 Feb/Mar 2011 Jan/Feb 2011 Aug/Sep 2009
Delafloxacin 450mg tablets and 300mg powder for concentrate for solution for infusion (Quofenix®) SMC2453	Treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of this infection.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	<a href="#">190</a>	August 2022
Delta-9-tetrahydrocannabinol	As treatment for symptom improvement in adult patients with	Not routinely available as local implementation plans are	<a href="#">191</a>	Nov 2022

2.7mg and cannabidiol 2.5mg per 100 microlitre spray (Sativex® Oromucosal Spray) SMC 2473	moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.	being developed - decision expected by April 2023		
Denosumab 60mg solution for injection in pre-filled syringe (Prolia®) SMC2117	Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.	Not available as not recommended for use in NHS Scotland	<a href="#">171</a>	Oct 2018
Denosumab 120mg solution for injection (Xgeva®) SMC No 2110	Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with haematological malignancies involving bone.	Not available as not recommended for use in NHS Scotland	<a href="#">170</a>	Sep 2018
Denosumab (Prolia®) (1013/14)	Osteoporosis in men at increased risk of fractures	Not recommended	<a href="#">143</a>	Nov/Dec 2014
Denosumab 120mg solution for injection (Xgeva®)  SMC No. 1119/15	Adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity	Not recommended	<a href="#">153</a>	Jan/Feb 2016
Denosumab (Xgeva®) (753/11)	Prevention of skeletal related events	Not recommended	<a href="#">113</a>	Jan 2012
Denosumab (Prolia®) (651/10)	Osteoporosis in postmenopausal women	GPs may prescribe under the direction of the Osteoporosis Clinic or Medicines for the elderly	<a href="#">112</a> <a href="#">Protocol</a> <a href="#">104</a> <a href="#">101</a>	Dec 2011 Mar 2011 Dec 10/Jan 2011
Denosumab (Prolia®) (670/10)	Bone loss associated with hormone ablation in men with prostate cancer	Not recommended	<a href="#">101</a>	Dec 2010/Jan 2011
Dermatophagoides	Adult patients (18-65 years) diagnosed by clinical history and a	Not available as not	<a href="#">194</a>	September 2023

<p>pteronyssinus and Dermatophagoides farinae oral lyophilisate (Acarizax®) SMC2613</p>	<p>positive test of house dust mite sensitisation (skin prick test and/or specific IgE) with at least one of the following conditions:</p> <ul style="list-style-type: none"> <li>– persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication</li> <li>– house dust mite allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe house dust mite allergic rhinitis. Patients' asthma status should be carefully evaluated before the initiation of treatment</li> </ul> <p>Adolescents (12-17 years) diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test and/or specific IgE) with persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication.</p>	<p>recommended for use in NHS Scotland</p>		
<p>Desmopressin (DDAVP Melt®) (358/07)</p>	<p>Diabetes insipidus</p>		<p><a href="#">68</a></p>	<p>May 2007</p>
<p>Desmopressin (DesmoMelt®) (357/07)</p>	<p>Nocturnal enuresis</p>	<p>Non-formulary</p>	<p><a href="#">68</a> <a href="#">60</a></p>	<p>May 2007 2006</p>
<p>Desmopressin 25 microgram, 50 microgram oral lyophilisate (Noqdirna®) SMC No. (1218/17)</p>	<p>Symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults. SMC restriction: For use in patients aged 65 years and over.</p>	<p>Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts</p>	<p><a href="#">160</a> <a href="#">163</a></p>	<p>Apr 2017 Sep 2017</p>
<p>Desogestrel (Cerazette®)</p>	<p>Oestrogen free contraceptive</p>		<p><a href="#">44</a> <a href="#">36</a> <a href="#">31</a> <a href="#">26</a></p>	<p>2003</p>

Dequalinium chloride 10mg vaginal tablets (Fluomizin®) SMC 1194/16	Treatment of bacterial vaginosis. SMC restriction: In patients for whom the initial treatment is not effective or well tolerated	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines ( <a href="#">Link to Formulary</a> )	<a href="#">158</a>	Dec 2016
Deucravacitinib film-coated tablets (Sotyktu) SMC2581	for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.  SMC restriction: patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra-indication to these treatments.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	196	February 2024
Dexamethasone 40mg tablets (Neofordex ®) SMC No 1322/18	In adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products.	Not available as not recommended in NHS Scotland	<a href="#">168</a>	May 2018
Dexamethasone (Ozurdex®) (1046/15)	For the treatment of adult patients with visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy.	Non Formulary - lack of clinician support	<a href="#">148</a>	May 2015
Dexamethasone implant (Ozurdex®) (751/11)	Adults with inflammation of the posterior segment of the eye	Not recommended	<a href="#">114</a>	Feb 2012
Dexamethasone implant (Ozurdex®) (652/10)	Adults with macular oedema	Non-formulary - absence of clinician demand	<a href="#">119</a> <a href="#">118</a> <a href="#">113</a> <a href="#">101</a>	Aug/Sept 2012 July 2012 Jan 2012 Dec 2010/Jan 2011
Dexmedetomidine 100	Sedation of non-intubated adult patients prior to and/or during	Not available as not	<a href="#">174</a>	May 2019

micrograms/ml concentrate for solution for infusion (Dexdor®) SMC 2161	diagnostic or surgical procedures requiring sedation, i.e. procedural/awake sedation.	recommended for use in NHS Scotland		
Dexmedetomidine (Dexdor®) (784/12)	Sedation in adult intensive care unit (ICU)	HOSPITAL ONLY (ICU)	<a href="#">118</a>	July 2012
Dexrazoxane (Cardioxane®) (419/07)	Chronic cumulative cardiotoxicity	Not recommended	<a href="#">74</a>	Nov 2007
Dexrazoxane (Savene®) (361/07)	Anthracycline extravasation	Not recommended	<a href="#">83</a> <a href="#">68</a>	Oct 2008 May 2007
Diamorphine hydrochloride 720 microgram/actuation and 1600 microgram/actuation nasal spray (Ayendi®) SMC (1172/16)	Treatment of acute severe nociceptive pain in children and adolescents in a hospital setting. Diamorphine hydro-chloride nasal spray should be administered in the emergency setting by practitioners experienced in the administration of opioids in children with appropriate monitoring.	Available in line with national guidance Hospital only (A&E)	<a href="#">156</a> <a href="#">157</a> <a href="#">160</a>	Sep 2016 Nov 2016 Apr 2017
Dibotermin alfa (InductOs®) (365/07)	Acute tibia fractures in adults	Not recommended	<a href="#">68</a>	May 2007
Diclofenac 4% spray gel Mobigel Spray®) (667/10)	Local symptomatic relief of mild to moderate pain and inflammation	Not recommended	<a href="#">101</a>	Dec 10/Jan 2011
Diclofenac 75mg/2ml injection (Dyloject®) (446/08)	Prevention of post-operative pain	HOSPITAL ONLY	<a href="#">77</a>	Mar 2008
Diclofenac gel patch (Voltarol®)	Epicondylitis and ankle sprain	Not recommended	<a href="#">54</a>	2005
Difelikefalin solution for injection (Kapruvia®) SMC2623	Treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	197 – Awaiting publication	Apr 2024
Dimethyl fumarate 30mg and 120mg gastro-resistant tablets	For the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy.	Available in line with national guidance	<a href="#">168</a>	May 2018

(Skilarence®) SMC No 1313/18	SMC restriction: for use in patients in whom other non-biologic systemic treatments (methotrexate, ciclosporin and acitretin) are not appropriate or have failed and who are considered unsuitable for biologic therapy given their current disease state or personal preference.			
Dimethyl fumarate (Tecfidera®) (886/13)	Treatment of adult patients with relapsing remitting multiple sclerosis	<a href="#">Available in line with local guidance for prescribing</a>	<a href="#">137</a>	Apr/May 2014
Dinoprostone (Propess®)	Cervical ripening	HOSPITAL ONLY	<a href="#">60</a>	2006
Dinutuximab beta 4.5mg/mL concentrate for solution for infusion (Qarziba®) SMC2105	For the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease. Prior to the treatment of relapsed neuroblastoma, any actively progressing disease should be stabilised by other suitable measures.	Available from a specialist centre in another NHS Board	<a href="#">172</a>	Dec 2018
Diroximel fumarate 231mg gastro-resistant hard capsules (Vumerity®) SMC2444	Treatment of adult patients with relapsing remitting multiple sclerosis. Diroximel fumarate provides an additional treatment choice in the therapeutic class of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activators.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	<a href="#">188</a>	April 2022
Docetaxel (Taxotere®)	Unresectable locally advanced or metastatic (Stage III/IV) NSCLC		<a href="#">26</a>	2003
Docetaxel (Taxotere®) (201/05)	Adjuvant treatment of operable, node +ve breast cancer	HOSPITAL ONLY (Oncology)	<a href="#">108</a> <a href="#">Protocol</a> <a href="#">100</a> <a href="#">54</a>	Aug 2011 Oct/Nov 2010 2005
Docetaxel (Taxotere®)	Hormone refractory metastatic prostate cancer (mHRPC)	HOSPITAL ONLY	<a href="#">108</a> <a href="#">Protocol</a>	Aug 2011



		(Oncology)	<a href="#">60</a> <a href="#">54</a>	2006 2005
Docetaxel (Taxotere®)	Metastatic gastric adenocarcinoma	Not recommended	<a href="#">63</a>	2006
Docetaxel (Taxotere®) (369/07)	Induction chemotherapy in advanced squamous cell carcinoma of the head and neck (SCCHN)	Non-formulary - absence of clinician support	<a href="#">116</a> <a href="#">68</a>	Apr/May 2012 May 2007
Docetaxel (Taxotere®) (481/08)	Induction treatment of patients with resectable locally advanced squamous cell carcinoma of the head and neck in combination with cisplatin and 5-fluorouracil	Non-formulary - pending protocol update	<a href="#">116</a> <a href="#">81</a>	Apr/May 2012 July 2008
Dolutegravir 50mg / lamivudine 300mg film-coated tablets (Dovato®) SMC2205	For the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.	Available in line with local guidance for prescribing (HIV clinic only)	<a href="#">177</a>	Dec 2019
Dolutegravir 50mg / rilpivirine 25mg film-coated tablets (Juluca®) SMC2091	The treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically-suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase inhibitor.  Dolutegravir plus rilpivirine was shown to be non-inferior to antiretroviral regimens containing a dual nucleos(t)ide reverse transcriptase inhibitor (NRTI) backbone plus a third agent (integrase inhibitor, protease inhibitor or NNRTI) in maintaining plasma HIV-1 RNA <50 copies/mL in two phase III randomised studies in virologically-suppressed adults.	Available in line with national guidance	<a href="#">171</a>	Oct 2018
Dolutegravir (Triumeq®) (1009/14)	HIV	Formulary - HOSPITAL ONLY (HIV Clinic)	<a href="#">144</a>	Jan/Feb 2015
Dolutegravir 10mg, 25mg, 50mg film-coated tablets (Tivicay®) SMC No. (1253/17)	in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected children aged >6 to 12 years of age. SMC has previously accepted dolutegravir 50mg film-coated tablets for use in	Available in line with national guidance	<a href="#">163</a>	Sep 2017

	combination with other anti-retroviral medicinal products for the treatment of HIV infected adults and adolescents above 12 years of age			
Dolutegravir (Tivicay®) (961/14)	HIV infected adults and adolescents above 12 years of age	HOSPITAL ONLY (HIV Service)	<a href="#">138</a>	May/June 2014
Donepezil orodispersible (Aricept Evess®)	Mild to moderately severe Alzheimer's dementia		<a href="#">66</a>	Feb 2007
Doravirine/lamivudine/tenofovir disoproxil fumarate 100mg/300mg/245mg film- coated tablets (Delstrigo®) SMC2333	For the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, lamivudine, or tenofovir.  Doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo®) offers an additional treatment choice of NNRTI-based single-tablet regimen for this indication.	Available in line with local guidance for prescribing	<a href="#">184</a>	May 2021
Doravirine 100mg film-coated tablets (Pifeltro®) SMC2332	In combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class.  Doravirine offers an additional treatment choice in the therapeutic class of NNRTIs for this indication.	Available in line with local guidance for prescribing	<a href="#">184</a>	May 2021
Doravirine 100mg / lamivudine 300mg / tenofovir disoproxil 245mg film-coated tablets (Delstrigo®) SMC 2163	Treatment of adults infected with human immunodeficiency virus 1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor class, lamivudine, or tenofovir.	Not available as not recommended for use in NHS Scotland	<a href="#">174</a>	May 2019
Doravirine 100mg film-coated tablets (Pifeltro®) SMC 2162	In combination with other antiretroviral medicinal products, for the treatment of adults infected with human immunodeficiency virus 1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor class.	Not available as not recommended for use in NHS Scotland	<a href="#">174</a>	May 2019

Doripenem (Doribax®)	Nosocomial pneumonia		<a href="#">89</a> <a href="#">87</a>	May 2009 March 2008
Doripenem (Doribax®) (529/09)	Complicated intra-abdominal infections in adults	Not recommended	<a href="#">89</a> <a href="#">86</a>	May 2009 Jan 2009
Dorzolamide (Trusopt®) unit dose eye drops	Ocular hypertension, glaucoma		<a href="#">59</a>	2006
Dorzolamide 2%/timolol maleate 0.5% (Cosopt®) unit dose eye drops	Glaucoma	Non-formulary	<a href="#">65</a>	Jan 2007
dostarlimab 500mg concentrate for solution for infusion (Jemperli®) SMC2404	As monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	<a href="#">188</a>	April 2022
Doxylamine succinate 10mg and pyridoxine hydrochloride 10mg gastro-resistant tablets (Xonvea®) SMC2140	The treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. Doxylamine in combination with pyridoxine significantly improved symptoms of nausea and vomiting compared with placebo in women with nausea and vomiting of pregnancy.	Not available as not recommended for use in NHS Scotland	<a href="#">175</a>	Aug 2019
Dronedarone (Multaq®)	Non-permanent atrial fibrillation (AF)	Specialist formulary list (Cardiology) - HOSPITAL ONLY	<a href="#">113</a> <a href="#">110</a> <a href="#">Protocol</a> <a href="#">99</a>	Jan 2012 Oct 2011 Aug/Sept 2010
Droperidol 2.5mg/mL solution for injection	PONV in adults	HOSPITAL ONLY - Acute Pain Specialist formulary list	<a href="#">123</a> <a href="#">93</a>	Jan 2013 Oct/Nov 2009
Drospirenone/ ethinylestradiol (Yasmin®) (23/03)	Combined oral contraceptive	Not recommended	<a href="#">105</a> <a href="#">25</a>	April/May 2011 2003
Drotrecogin alfa (activated)	Severe sepsis	Withdrawn	<a href="#">21</a>	2002

(Xigris®) *Withdrawn October 2011				
Dulaglutide 0.75mg and 1.5mg solution for injection in pre-filled pen (Trulicity®) SMC No. 1110/15	In adults with type 2 diabetes mellitus to improve glycaemic control	Available in line with local guidance for prescribing	<a href="#">153</a> <a href="#">154</a>	Jan/Feb 2016 May 2016
Duloxetine (Cymbalta®) (514/08)	Generalised anxiety disorder	Not recommended	<a href="#">83</a>	Oct 2008
Duloxetine (Cymbalta®)	Diabetic peripheral neuropathic pain (DPNP)	Non-formulary	<a href="#">61</a>	2006
Duloxetine (Cymbalta®)	Major depressive episodes	Formulary (Mental Health specialist list)	<a href="#">117</a> <a href="#">53</a>	May/June 2012 2005
Duloxetine (Yentreve®)	Stress incontinence		<a href="#">45</a>	2004
Dupilumab 200mg and 300mg solution for injection in pre-filled syringe and pen (Dupixent®) SMC2317	Indication under review: in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment. SMC restriction: for the treatment of patients with blood eosinophils $\geq 150$ cells/microlitre and FeNO $\geq 25$ parts per billion, and $\geq 4$ exacerbations in the preceding year, who have previously received biologic treatment with anti-IgE or anti-IL-5 therapies. In a phase III study dupilumab, compared with placebo, reduced asthma exacerbation rates and was associated with greater improvements in lung function, in patients with asthma	available in line with national guidance	<a href="#">184</a>	May 2021

	uncontrolled with medium to high dose ICS plus one or two controller medicines.			
Dupilumab 300mg solution for injection in pre-filled pen and 300mg solution for injection in pre-filled syringe (Dupixent®) SMC2324	Indication under review: As an add-on therapy with intranasal corticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyposis for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control	Not available as not recommended for use in NHS Scotland	183	Awaiting publication
Dupilumab 200mg and 300mg solution for injection in pre-filled syringe (Dupixent®) SMC 2232	The treatment of moderate-to-severe atopic dermatitis in adolescents ( $\geq 12$ to $< 18$ years) who are candidates for systemic therapy.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	<a href="#">179</a>	Apr 2020
Dupilumab 300mg solution for injection in pre-filled syringe (Dupixent®) SMC2011	The treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.  SMC restriction: patients who have had an inadequate response to existing systemic immunosuppressants such as ciclosporin, or in whom such treatment is considered unsuitable.	<a href="#">Available in line with local guidance for prescribing</a>	<a href="#">171</a>	Oct 2018
Dupilumab 300 mg solution for injection in pre-filled syringe or pre-filled pen (Dupixent®) SMC2598	For the treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy.	Available in line with local guidance	197 – Awaiting publication	Apr 2024
Durvalumab concentrate for solution for infusion (Imfinzi®) SMC2582	In combination with gemcitabine and cisplatin for the first-line treatment of adults with locally advanced, unresectable, or metastatic biliary tract cancer.	Available in line with national guidance	<a href="#">195</a>	December 2023
durvalumab 50mg/mL concentrate for solution for		Not available as not recommended for use in	<a href="#">188</a>	April 2022

infusion (Imfinzi®) SMC2434		NHS Scotland		
Durvalumab 50mg/mL concentrate for solution for infusion (Imfinzi®) SMC2156	As monotherapy for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 [programmed cell death ligand 1] on $\geq 1\%$ of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy.	Available in line with local guidance for prescribing.	<a href="#">175</a>	Aug 2019
Dutasteride (Combodart®) (628/10)	BPH	Non-formulary	<a href="#">101</a> <a href="#">100</a> <a href="#">99</a>	Dec 2010/Jan 2011 Oct/Nov 2010 Aug/Sept 2010
Dutasteride (Avodart®)	BPH		<a href="#">44</a> <a href="#">26</a>	2003

Updated: 15th March 2024

[Back to top](#)

[Back to homepage](#)